Clinical Treatment in Colorectal Cancer: Other Aspects



In this chapter we will discuss current concepts in the treatment of colorectal cancer (CRC)—surgery, chemotherapy, and radiotherapy. We will explain how to choose the adequate treatment approach and answer the following questions: When complete surgical removal is indicated, should chemotherapy be applied before, or instead after, the surgery? Is radiotherapy an option in colorectal cancer? We will widely discuss the surgical approaches in the CRC and currently available drugs (their medical indications, mechanism of action, spectrum of adverse effects). Moreover, we will delineate further perspectives in the CRC management—DNA sequencing, the role of small interfering RNA, and microRNA.


Colorectal cancer Colorectal cancer chemotherapy Colorectal cancer radiotherapy 





Carcinoembryonic antigen


Colorectal cancer


Epidermal growth factor receptor


Food and Drug Administration


Double-action formula of 5-fluorouracil and oxaliplatin


Triple-action formula of 5-fluorouracil, leucovorin, and irinotecan


Triple-action formula of 5-fluorouracil, leucovorin, and oxaliplatin




Metastatic colorectal cancer


Vascular endothelial growth factor



The authors have no conflicts of interest to disclose.

Supported by grants from the Medical University of Lodz (502-03/1-156-04/502-14-297 to MZ), National Science Centre (#UMO-2013/11/N/NZ7/00724 and UMO-2014/12/T/NZ7/00252 to MZ), and Ministry of Science and Higher Education (Iuventus Plus 5 Program #IP2015 089474 to MZ). AJ and MZ are recipients of the Polish L’Oréal-UNESCO Awards for Women in Science. MZ is a recipient of Polpharma Scientific Foundation Scholarship.


  1. 1.
    Sievers CK, Kratz JD, Zurbriggen LD, Loconte NK, Lubner SJ, Uboha N, et al. The multidisciplinary management of colorectal cancer: present and future paradigms. Clin Colon Rectal Surg. 2016;1(212):232–8.CrossRefGoogle Scholar
  2. 2.
    National Comprehensive Cancer Network. Colon Cancer (version 2.2017) [Internet]. Available from: [cited 20 Jul 2005].
  3. 3.
    FOxTROT Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13(11):1152–60. Available from: CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345(8955):939–44. Available from: CrossRefGoogle Scholar
  5. 5.
    Pardini B, Kumar R, Naccarati A, Novotny J, Prasad RB, Forsti A, et al. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol. 2011;72(1):162–3. Available from: CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 2006;32(7):491–503. Available from: CrossRefPubMedGoogle Scholar
  7. 7.
    Rothenberg ML. Efficacy of oxaliplatin in the treatment of colorectal cancer. Oncology. 2000;14(12 Suppl 11):9–14. Available from: PubMedGoogle Scholar
  8. 8.
    Bleyer WA. New vistas for leucovorin in cancer chemotherapy. Cancer. 1989;63(6 Suppl):995–1007. Available from: CrossRefPubMedGoogle Scholar
  9. 9.
    Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manag Res. 2011;3:79–89. Available from: PubMedPubMedCentralGoogle Scholar
  10. 10.
    Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257–71. Available from: CrossRefPubMedGoogle Scholar
  11. 11.
    McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68(4):487–506. Available from: CrossRefPubMedGoogle Scholar
  12. 12.
    Weber J, McCormack PL. Panitumumab: in metastatic colorectal cancer with wild-type KRAS. BioDrugs. 2008;22(6):403–11. Available from: CrossRefPubMedGoogle Scholar
  13. 13.
    National Cancer Institute at the National Institutes of Health. FDA Approval for Cetuximab. 2013. Available from:
  14. 14.
    Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. doi: 10.1016/S0140-6736(12)61900-X.CrossRefPubMedGoogle Scholar
  15. 15.
    Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8(3):230–42. Available from: CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    National Cancer Institute at the National Institutes of Health. Trifluridine and Tipiracil Hydrochloride. 2015. Available from:
  17. 17.
    FDA approves new oral medication to treat patients with advanced colorectal cancer. 2015; Available from:
  18. 18.
    FDA Approval for Ziv-Aflibercept. 2013. Available from:
  19. 19.
    De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594–603. Available from: CrossRefPubMedGoogle Scholar
  20. 20.
    Bäumer S, Bäumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, et al. Antibody-mediated delivery of anti–KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin Cancer Res. 2015;21(6):1383–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of MicroRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68(11):4123–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28(10):1385–92. Available from: CrossRefPubMedGoogle Scholar
  23. 23.
    Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J. 2012;18(3):244–52. Available from:; CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bartos A, Bartos D, Szabo B, Breazu C, Opincariu I, Mironiuc A, et al. Recent achievements in colorectal cancer diagnostic and therapy by the use of nanoparticles. Drug Metab Rev. 2016;2532(February):1–17. Available from: Google Scholar
  25. 25.
    Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797–806. Available from: CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Biochemistry, Faculty of MedicineMedical University of LodzLodzPoland

Personalised recommendations